AMEX: NHC · Medical Care Facilities
National HealthCare (NHC) fair value and price range
As of 14 Nov 2026, Faircurve's model values National HealthCare (NHC) at $249.00 a share. The stock last closed at $207.19, which puts the model's fair value 20.2% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 16 Nov 2026. National HealthCare Corporation.
The report adds the live price and the chart against the range the options market prices. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 held the fair value at $249.00, within 1% of the run of 7 Nov 2026.
What the model makes of itThe price of $207.19 is 20.2% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNo report date on file. Options prices imply a move of about 11% either way over the next month. On the model's Scorecard Leaders list since 9 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give NHC?
The calibrated range for NHC over 63 trading days is $181.94 to $237.49. It sits around the last close, and its width comes from the volatility that NHC's own options imply (39% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $130.45 to $442.21. In 60% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
National HealthCare Corporation (NHC) is a prominent provider in the healthcare sector. It runs, manages and provides services for a wide range of elder care and health facilities.
Faircurve's model put the fair value at $249.00 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $249.64, a move of -0.3%. The calibrated range over 63 trading days runs from $184.80 to $235.35. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence as low, so no verdict is shown. The grade looks at input completeness, the number and agreement of comparable companies, and the width of the range of outcomes. It does not say whether the fair value is right.
The model's overall quality score is 61 out of 100. Earnings quality scores 100, with FCF / net income at 1.53x against a peer median of 1.08x. Stability scores 28, with five-year EBITDA margin downside volatility at 3.0 pts against a peer median of 0.7 pts. Profitability scores 36, with ROIC at 7.5% against a peer median of 9.6%. The model compares the company with Hims & Hers Health, Inc. (HIMS), Addus HomeCare Corporation (ADUS), Option Care Health, Inc. (OPCH), Concentra Group Holdings Parent, Inc. (CON) and Healthcare Services Group, Inc. (HCSG).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does NHC report earnings, and how has the stock reacted?
Options prices on 16 Nov 2026 imply a move of about 9.2% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. NHC's 30 day implied volatility works out to about 11.4% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across NHC's last 8 reports, ignoring direction, was 3.6%.
What the options market has priced for a month's move in NHC
How does NHC score on business quality?
National HealthCare's overall quality score is 61 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 36 | 7.5%ROIC | 9.6% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 100 | 1.53xFCF / net income | 1.08x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 69 | 16.9%Revenue growth, trailing | 16.3% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 76 | 0.9%Net buybacks / market value | 0.3% |
| Balance sheetNet debt to EBITDA and interest coverage. | 59 | 2.17xNet debt / EBITDA | 3.45x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 28 | 3.0 ptsEBITDA margin downside volatility, 5y | 0.7 pts |
How does NHC compare with similar companies?
The companies in medical care facilities closest to National HealthCare in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| ACHC Acadia Healthcare Company, Inc. | $38.70 | $44.44 | +14.8% | Low evidence grade |
| MD Pediatrix Medical Group, Inc. | $31.89 | $35.38 | +10.9% | Low evidence grade |
| HIMS Hims & Hers Health, Inc. | $18.56 | $21.46 | +15.6% | Undervalued |
| ADUS Addus HomeCare Corporation | $124.61 | $133.49 | +7.1% | Fairly valued |
| OPCH Option Care Health, Inc. | $31.71 | $32.92 | +3.8% | Fairly valued |
| CON Concentra Group Holdings Parent, Inc. | $43.44 | $43.92 | +1.1% | Fairly valued |
| HCSG Healthcare Services Group, Inc. | $24.86 | $24.39 | -1.9% | Fairly valued |
| ASTH Astrana Health, Inc. | $32.87 | $38.40 | +16.8% | Low evidence grade |
What the comparable companies' multiples alone would give for NHC, the peer-implied price, is $241.09 a share on this run. The fair value weighs that against the company's own multiple.
All medical care facilities stocks ranked by gap to fair value
National HealthCare at a glance
National HealthCare Corporation (NHC) is a prominent provider in the healthcare sector, involved in the operation, management, and service provision for a wide array of elder care and health facilities.
- Market value
- $3.3B
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Beta to the US market
- 0.21
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices National HealthCare on the value of the whole business against its operating profit, compared with where that ratio has sat before (EV/EBITDA against its own history), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for NHC was $249.64. As of 14 Nov 2026 it is $249.00, a change of -0.3%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about National HealthCare's valuation
Is National HealthCare stock undervalued or overvalued?
Faircurve's model puts NHC's fair value at $249.00 a share against a last close of $207.19, as of 14 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is NHC's fair value?
$249.00 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $130.45 to $442.21.
What price range does the model give NHC?
$181.94 to $237.49 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
How much has NHC moved on past earnings reports?
Across its last 8 reports the median two session move was 3.6%, ignoring direction. The largest was +10.7% around the report of 8 May 2026.
How confident is the model in this valuation?
The model's evidence grade for NHC is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on NHC
The model has an idea open on NHC under Scorecard Leaders since 9 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on NHC with their outcomes. A free account is enough.